- Trials with a EudraCT protocol (297)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
297 result(s) found for: Relapsing-remitting.
Displaying page 7 of 15.
EudraCT Number: 2010-023856-97 | Sponsor Protocol Number: 205MS302 | Start Date*: 2011-09-22 | |||||||||||
Sponsor Name:Biogen Idec Limited | |||||||||||||
Full Title: A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Immunogenicity and Pharmacokinetics of BIIB019, Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneo... | |||||||||||||
Medical condition: Relapsing-remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006323-39 | Sponsor Protocol Number: SuniMS-03 | Start Date*: 2007-06-19 |
Sponsor Name:Charité-Universitätsmedizin Berlin | ||
Full Title: Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis | ||
Medical condition: relapsing-remitting multiple sclerosis ICD classification: G35.1 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000559-26 | Sponsor Protocol Number: PRAG-MS | Start Date*: 2017-09-14 | |||||||||||||||||||||
Sponsor Name:FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA | |||||||||||||||||||||||
Full Title: A multicentric randomized PRAGmatic trial to compare the effectiveness of fingolimod versus dimethyl-fumarate on patient overall disease experience in relapsing remitting Multiple Sclerosis: novel... | |||||||||||||||||||||||
Medical condition: relapsing-remitting multiple sclerosis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002351-15 | Sponsor Protocol Number: EMR200559006 | Start Date*: 2014-03-13 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 µg IM Weekl... | |||||||||||||
Medical condition: Relapsing remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Prematurely Ended) LV (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006262-40 | Sponsor Protocol Number: 215MS201 | Start Date*: 2013-06-18 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects with Relapsing Forms of ... | ||||||||||||||||||
Medical condition: Relapsing forms of multiple sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) IT (Completed) NL (Completed) HU (Completed) ES (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003231-30 | Sponsor Protocol Number: Linitox | Start Date*: 2018-10-19 | ||||||||||||||||||||||||||
Sponsor Name:Aránzazu Vázquez Doce | ||||||||||||||||||||||||||||
Full Title: EFFECTIVENESS OF THE REPEATED INFILTRATIONS OF BOTULINUM TOXIN A IN THE GAIT AND QUALITY OF LIFE IN ADULTS WITH SPASTIC PARAPARESIA SECONDARY TO MULTIPLE SCLEROSIS | ||||||||||||||||||||||||||||
Medical condition: Multiple sclerosis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004622-29 | Sponsor Protocol Number: 101MS408 | Start Date*: 2014-11-10 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Open-Label Study to Assess the Impact of Natalizumab versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Scleros... | |||||||||||||
Medical condition: Multiple Sclerosis (MS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) CZ (Completed) GB (Prematurely Ended) SE (Prematurely Ended) ES (Completed) DE (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001656-35 | Sponsor Protocol Number: 109MS408 | Start Date*: 2014-04-07 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects with Relapsing-Remitting Multipl... | ||||||||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) HU (Completed) BE (Completed) PT (Completed) IT (Completed) CZ (Completed) SK (Completed) ES (Completed) SI (Completed) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-003735-32 | Sponsor Protocol Number: AB11005 | Start Date*: 2015-04-01 |
Sponsor Name:AB Science | ||
Full Title: A 96-weeks, prospective, multicentre, randomised, open label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to first line treatment, in patients w... | ||
Medical condition: Prospective, multicentre, randomised, open-label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib at 3 mg/kg/day with switch to 4.5 then 6 mg/kg/day... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SK (Prohibited by CA) GR (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-005597-38 | Sponsor Protocol Number: MA30005 | Start Date*: 2016-05-19 | ||||||||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||
Full Title: An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modify... | ||||||||||||||||||||||||||||
Medical condition: Relapsing remitting multiple sclerosis (RRMS) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) SE (Completed) ES (Ongoing) EE (Completed) DK (Completed) DE (Completed) NL (Completed) BE (Completed) CZ (Completed) FI (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-001294-16 | Sponsor Protocol Number: ALK8700-A302 | Start Date*: 2017-09-22 | |||||||||||
Sponsor Name:Alkermes, Inc. | |||||||||||||
Full Title: A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate | |||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020315-36 | Sponsor Protocol Number: WA21093 | Start Date*: 2011-10-18 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche | |||||||||||||
Full Title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... | |||||||||||||
Medical condition: Relapsing Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) BE (Completed) SE (Completed) DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) BG (Completed) FR (Completed) IE (Completed) IT (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023048-34 | Sponsor Protocol Number: NT-KO-003-2010-01 | Start Date*: 2011-04-28 | |||||||||||
Sponsor Name:NEUROTEC PHARMA, S.L | |||||||||||||
Full Title: Ensayo Clínico Fase IIa, Multicéntrico, Doble Ciego para Evaluar la Eficacia y Seguridad de dosis bajas de Diazoxida oral en el tratamiento de la Esclerosis Múltiple | |||||||||||||
Medical condition: Tratamiento de la Esclerosis Múltiple. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000221-20 | Sponsor Protocol Number: Nano-Cl_iv | Start Date*: 2014-10-23 |
Sponsor Name:University Hospital Zürich | ||
Full Title: Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – a Phase IIa Clinical Trial | ||
Medical condition: Clinically Isolated Syndrome and Relapsing-remitting Multiple Sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004128-41 | Sponsor Protocol Number: WN42086 | Start Date*: 2021-08-24 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICACY OF OCRELIZUMAB IN COMPARISON WITH FINGOLIMOD IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTI... | |||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) BG (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005086-12 | Sponsor Protocol Number: GAM-27 | Start Date*: 2013-07-05 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis. | |||||||||||||
Medical condition: relapsing multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) HU (Completed) DE (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001280-49 | Sponsor Protocol Number: CFTY720DFR03 | Start Date*: 2011-06-14 | |||||||||||
Sponsor Name:Novartis Pharma S.A.S | |||||||||||||
Full Title: « GRACE : Gilenya® - Réponse Au Coping - Evaluation » Etude multicentrique de phase IV, prospective, en ouvert, d'une durée de 4 mois, visant à comparer la réponse à l’initiation du fingolimod (Gil... | |||||||||||||
Medical condition: Sclérose en plaques rémittente-récurrente active | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000780-91 | Sponsor Protocol Number: ML40359 | Start Date*: 2018-04-26 | |||||||||||||||||||||
Sponsor Name:ROCHE | |||||||||||||||||||||||
Full Title: AN OPEN-LABEL, SINGLE-ARM PHASE IV STUDY TO ASSESS OCRELIZUMAB EFFICACY, SAFETY AND IMPACT ON PATIENT REPORTED OUTCOMES (PROS) IN PATIENTS WITH ACTIVE RELAPSING MULTIPLE SCLEROSIS (PRO-MSACTIVE) | |||||||||||||||||||||||
Medical condition: ACTIVE RELAPSING MULTIPLE SCLEROSIS (Active RMS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-001437-16 | Sponsor Protocol Number: CFTY720D2319 | Start Date*: 2012-09-19 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 3-year, multi-center study to evaluate optical coherence tomography as an outcome measure in patients with multiple sclerosis | |||||||||||||
Medical condition: multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000840-32 | Sponsor Protocol Number: CUEBS_2016 | Start Date*: 2016-06-24 | ||||||||||||||||
Sponsor Name:FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA | ||||||||||||||||||
Full Title: Clinical and Urodynamic Evaluation of Bladder dysfunction in multiple sclerosis patients treated with Sativex | ||||||||||||||||||
Medical condition: Multiple Sclerosis patients treated with nabiximols (Sativex¿, Almirall) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
